Jawad Thamer, MD
Internal Medicine · Dearborn, MINPI 1972573731
Payments from drug & device makers
Across 111 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$412
- Amgen$288
- AstraZeneca$279
- Novo Nordisk$235
- Pfizer$219
- Exact Sciences$216
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,769100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $412 |
| Amgen | 11 | $288 |
| AstraZeneca | 16 | $279 |
| Novo Nordisk | 12 | $235 |
| Pfizer | 10 | $219 |
| Exact Sciences | 6 | $216 |
| Boston Scientific | 2 | $170 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Mylan Specialty L.p. | 4 | $108 |
| Dexcom, Inc. | 3 | $92 |
| AbbVie | 4 | $91 |
| GSK | 4 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 1 | $65 |
| Abiomed | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $38 |
| Shield Therapeutics Inc | 2 | $34 |
| Novartis | 2 | $32 |
| Abbott | 2 | $30 |
| Nevro Corp. | 1 | $27 |
| Medtronic | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,769 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 314 | $164,061 |
| JanuviaSitagliptin Phosphate | 133 | $86,135 |
| OzempicSemaglutide | 62 | $68,514 |
| JardianceEmpagliflozin | 91 | $55,505 |
| XifaxanRifaximin | 13 | $51,561 |
| EntrestoSacubitril/Valsartan | 52 | $35,403 |
| FarxigaDapagliflozin Propanediol | 46 | $34,055 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $23,261 |
| GenotropinSomatropin | 12 | $20,690 |
| Dalfampridine ErDalfampridine | 13 | $20,444 |
| VraylarCariprazine Hcl | 11 | $15,475 |
| TrulicityDulaglutide | 15 | $14,424 |
| XareltoRivaroxaban | 29 | $14,223 |
| MounjaroTirzepatide | 12 | $12,510 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $11,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Genotropin | $219 | $184,751326 claims |
| Novo NordiskOzempic | $235 | $68,51462 claims |
| Boehringer IngelheimJardiance, Tradjenta | $24 | $64,151114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $279 | $52,59286 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $68 | $51,56113 claims |
| NovartisEntresto | $32 | $35,40352 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $412 | $26,93427 claims |
| GSKBreo Ellipta | $78 | $23,26138 claims |
| AbbVieVraylar, Linzess | $91 | $20,96922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Dearborn
- Abdulhassan SaadDearborn$11.5M
- Ali HazimehDearborn$1.5M
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.